This is a working overview of prohibited substance, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-25 and is reviewed periodically as new material appears.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
As an isolate - through the process of wet fractionation which produces a high protein concentration As a concentrate - through the process of dry fractionation which produces a low protein concentration In textured form, which is when it is used in food products as a substitute for other products, such as meat alternatives Pea protein has low allergenicity and high nutritional value. It is common as a source of protein in vegan and vegetarian food, and in protein supplement products.
The Japanese vocaloid song Housenka (鳳仙花, which translates to Impatiens balsamina) describes a person who doesn't fit in with a social group despite wanting to. In the music video, the singer laments this fate and compares herself to the plant. She references its "touch-me-not" nickname and the Hedgehog's Dilemma-esque explosive dehiscence of its seeds by saying: "Don't touch me," the balsam [says], fallen silent. And yet it can't leave seeds unless it breaks from its shell. Hong Nan-pa's 1919 "Bongseonhwa", called Korea's first Western-style song, was named for the flower (bongseonhwa [봉선화] in Korean). In it, Hong uses the analogy of a spent I. balsamina in autumn for Korea under Japanese colonial rule, with the hope for rebirth in the spring. Several South Korean films and dramas, including the 1956 movie A Touch-Me-Not (Bongseonhwa), are also named for the flower.
The program features engineers and architects from around the world, including Santiago Calatrava; italian structural engineer Mario Salvadori of Columbia University; Danish civil engineer and bridge designer Klaus Ostenfeld, and grandson of civil engineer Asger Ostenfeld; civil engineer Mark Whitby and the innovative Severn Bridge, which deployed box girders; Irish civil engineer Patrick J. Dowling, head of the Department of Civil and Environmental Engineering, Imperial College London; the Severn Bridge was taking much heavy traffic at 4-6 am each weekday morning, the amounts of heavy traffic that it had not been inherently designed for, in the late 1950s to take, and the bridge was strengthened in 1990; David Blockley, head of civil engineering at the University of Bristol, and earthquake protection; the 1989 Loma Prieta earthquake; Colin Taylor, head of civil engineering from 2006-11 at the University of Bristol; the Jinde Bridge; the Japanese Great Seto Bridge opened in April 1988; the Pont de Normandie was twice as large of any previous similar type of bridge, and its 206m towers were completed in July 1993, being 250m longer than the 1993 Yangpu Bridge; French civil engineer Michel Virlogeux, and the project manager Bertrand Deroubaix; tuned mass dampers; Spanish structural engineer Santiago Calatrava, who designed the 1992 Alamillo Bridge and 1991 Lusitania Bridge in Mérida, Spain; Peter Head (civil engineer) of Maunsell Group (now AECOM).
Sources: en.wikipedia.org
Open-angle glaucoma usually presents with no symptoms early in the course of the disease, but it may gradually progress to involve difficulties with vision. It usually involves deficits in the peripheral vision followed by central vision loss as the disease progresses, but less commonly it may present as central vision loss or patchy areas of vision loss. On an eye examination, optic nerve changes are seen indicating damage to the optic nerve head (increased cup-to-disc ratio on fundoscopic examination). Acute angle-closure glaucoma, a medical emergency due to the risk of impending permanent vision loss, is characterized by sudden ocular pain, seeing halos around lights, red eye, very high intraocular pressure, nausea and vomiting, and suddenly decreased vision. Acute angle-closure glaucoma may further present with corneal edema, engorged conjunctival vessels, and a fixed and dilated pupil on examination. Opaque specks may occur in the lens in glaucoma, known as glaukomflecken. The word is German, meaning "glaucoma-specks".
== Histopathology == Although the exact cause of this condition is not known, it is an inflammatory disorder characterized by collagen degeneration, combined with a granulomatous response. It always involves the dermis diffusely, and sometimes also involves the deeper fat layer. Commonly, dermal blood vessels are thickened (Microangiopathy). It can be precipitated by local trauma, though it often occurs without any injury. As a metabolically driven skin disorder, the pathology is characterized by poor intracellular glucose utilization leading to metabolically stressed fibroblasts. Despite an increased GLUT-1 response, fibroblasts in NL fail to produce normal collagen, weakening and breaking down the skin's structure. Vascular impairments reduce oxygen and nutrient circulation, creating hypoxia and tissue breakdown.
=== Contributions to mechanical properties of biomaterials === Natural materials show a combination of normally contradicting mechanical properties (softness and toughness), due to their hierarchical structures of fibrils across multiple length scales. These fibrils are often oriented in a single direction, leading to anisotropic mechanical response in the resulting biocomposite material. This is a prime advantage as most of these materials withstand stresses in a single direction, and so a higher yield and fracture stress in the direction of the applied stress ensures the material structural integrity. Macro, micro, and nano fibrils enable the material to resist fracture through a series of fracture resistance mechanisms:
Sources: en.wikipedia.org
== Medical uses == In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people inadequately controlled on their maximal tolerated dose of metformin and a sulfonylurea; as triple combination therapy with a peroxisome proliferator-activated receptor (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist; and as add-on to insulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and metformin alone do not provide adequate glycemic control." In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes. The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.
In January 2021, the United States designated the Houthis a terrorist organization, creating fears of an aid shortage in Yemen, but this stance was reversed a month later after Joe Biden became president. On 17 January 2022, Houthi missile and drone attacks on UAE industrial targets set fuel trucks on fire and killed three foreign workers. This was the first specific attack to which the Houthi admitted, and the first to result in deaths. A response led by Saudi Arabia included a 21 January air strike on a detention centre in Yemen, resulting in at least 70 deaths. Following the outbreak of the Gaza war, the Houthis began to fire missiles at Israel and to attack ships off Yemen's coast in the Red Sea, which they say is in solidarity with the Palestinians and aiming to facilitate entry of humanitarian aid into the Gaza Strip. On 31 October Houthi forces launched ballistic missiles at Israel, which were shot down by Israel's Arrow missile defense system. Israeli officials claimed that this was the first ever combat to occur in space. In order to end the attacks in the Red Sea, the Houthis demanded a ceasefire in Gaza and an end to Israel's blockade of the Gaza Strip. In January 2024, the United States and the United Kingdom conducted airstrikes against multiple Houthi targets in Yemen, and the United States designated the Houthi as a Specially Designated Global Terrorist (SDGT). In February 2026, the Houthis announced that they had resumed attacks on ships in response to the recent US and Israeli airstrikes on Iran.
A fundamental distinction in evidence-based practice is between observational studies and randomized controlled trials. Types of observational studies in epidemiology, such as the cohort study and the case-control study, provide less compelling evidence than the randomized controlled trial. In observational studies, the investigators retrospectively assess associations between the treatments given to participants and their health status, with potential for considerable errors in design and interpretation. A randomized controlled trial can provide compelling evidence that the study treatment causes an effect on human health. Some phase II and most phase III drug trials are designed as randomized, double-blind, and placebo-controlled.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.